Advancing Clinical Evaluation and Treatment of Arthrogenic Muscle Inhibition: A Need for Validation and Innovation—Letter to the Editor

Grant E. Norte; David A. Sherman; Justin L. Rush; Christopher D. Ingersoll; Stephan G. Bodkin; Lynn Snyder-Mackler; Terry L. Grindstaff; Julie P. Burland; J. Ty Hopkins; Troy Blackburn; Meredith Chaput; Yu Konishi; David A. Rice; Joseph M. Hart; Matthew S. Harkey; Ryan Zarzycki; Riann M. Palmieri-Smith; Lindsey K. Lepley; Adam S. Lepley; Derek N. Pamukoff; Jihong Park; Caroline Lisee; Brian Pietrosimone; Abbey C. Thomas; John Goetschius; Timothy W. Tourville; Dawon J. Kidgell; Christopher M. Kuenze

Article

Advancing Clinical Evaluation and Treatment of Arthrogenic Muscle Inhibition: A Need for Validation and Innovation—Letter to the Editor

American Journal of Sports Medicine

DOI: 10.1177/03635465241272410

4Citations

6Readers

Get full text

Cite

CITATION STYLE

APA

Norte, G. E., Sherman, D. A., Rush, J. L., Ingersoll, C. D., Bodkin, S. G., Snyder-Mackler, L., … Kuenze, C. M. (2024, October 1). Advancing Clinical Evaluation and Treatment of Arthrogenic Muscle Inhibition: A Need for Validation and Innovation—Letter to the Editor. American Journal of Sports Medicine. SAGE Publications Inc. https://doi.org/10.1177/03635465241272410

Advancing Clinical Evaluation and Treatment of Arthrogenic Muscle Inhibition: A Need for Validation and Innovation—Letter to the Editor

Cite

Register to see more suggestions